World-class company that leads
Japan’s healthcare industry
Yutaro Shintaku
Director and Managing Executive Officer
Strategy Planning Dept.
Terumo CorporationMay 12, 2010
1/12

Significant shift inbusiness environment
Rising healthcare demands in China, Asia,
other emerging economies- Rapid development of healthcare infrastructureHealthcare reforms in US and EU- Increasing focus on healthcare economy

Growing expectation in Japan as a strategic
industry for economic growth- Application of advanced technologies for bettermedical outcome

2/12Terumo’s new directions for growth
Cardiac andvascular
EU / USOtherbusinesses

CAGR
15% in thelast 5yrs

China / Asia /Others
3/12

Enhanced global management
Management led by associates’
individual initiatives
 Development of global leaders Infrastructure for better management ：SCM/IT ...

Speed and Global Perspective
4/12

Pursuit of new growth opportunities① Value added drug delivery devices catered forbiomedicine② Global diabetes management business③ Transfusion as a basic healthcare infrastructure④ Further expansion of the minimally invasive procedures⑤ Growth of Left Ventricular Assist Device driven bydestination therapy
5/12

Pursuit of new growth opportunities① Value added drug delivery devices
catered for biomedicine
CurrentFuture

Synthetic Medicine

Biomedicine

Oral administration

Injection

Biomedicine market$120 billion⇒$200 billion in ten years

Growing demands of value added drugdelivery device catered for biomedicine
6/12

Pursuit of new growth opportunities② Global diabetes managementbusiness
Diabetics undergoing blood glucose control:- Number is expected to triple or quadruple world-wide- China, Asia and other emerging markets outgrow developed
countries

Diabetes related complications lower quality oflife and uplift medical expenditure

Growth opportunities inmanagement of diabetes
7/12

Pursuit of new growth opportunities③ Transfusion as a basic healthcare
infrastructure
Developed countries:

Needs of efficient blood processing

Emerging countries:

Buildup of blood supply system-WHO estimate of minimally needed number of donation,
1% of population, will be reached-Number of donation from 30 million to 150 million

Transfusion business will enter thenew era of growth
8/12

Pursuit of new growth opportunities④ Further expansion of minimallyinvasive procedures
Application of catheter technologies-Coronary ⇒ Neuro, peripheral and orthopedic etc.
-Japanese refined manufacturing and high quality

Shift towards minimally invasive surgical procedures-Open surgery ⇒ Robotic surgery-Shorter recovery period by management of nutrition andpain
9/12

Pursuit of new growth opportunities⑤Growth of Left Ventricular Assist Device
driven by destination therapy
Bridge to transplant
Market size: $200 million ～Reduced size&
Higher reliability+Destination therapy
Market size of $2 billion in 2020

＋Bridge to recovery
Market size of $5 billion after 2025
10/12

World-class company that leads
Japan’s healthcare industry

Exceed sales of ¥1 trillion
by 2020
11/12

IR Contact
TERUMO Corporation
Corporate Communication (IR) Dept.
E-mail: kouhou_terumo01@terumo.co.jp
Among the information that Terumo discloses, forecasts of financial
performance on future projections contain potential risks and uncertainty
since these are forecasts on projections made by Terumo based on limited
information available at the moment of disclosure. Accordingly, it should be
noted that actual results may differ from those forecasts on projections due
to various factors. Factors affecting to actual results include, but are notlimited to, changes in economic conditions surrounding Terumo, fluctuationsof foreign exchange rates, and state of competition.
The market share information in this booklet is partly derived from our own
independent research.

12/12